Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 209

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients

Open access
Vroonen, Laurent, Jaffrain-Rea, Marie-Lise, Petrossians, Patrick, Tamagno, Gianluca, Chanson, Philippe, Vilar, Lucio, Borson-Chazot, Françoise, Naves, Luciana A, Brue, Thierry, Gatta, Blandine, Delemer, Brigitte, Ciccarelli, Enrica, Beck-Peccoz, Paolo, Caron, Philippe, Daly, Adrian F, Beckers, Albert · 2012 · European Journal of Endocrinology

Abstract

Background: Dopamine agonist resistance in prolactinoma is an infrequent phenomenon. Doses of cabergoline (CAB) of up to 2.0 mg/week are usually effective in controlling prolactin (PRL) secretion and reducing tumor size in prolactinomas. The clinical presentation, management, and outcome of patients that are not well controlled by such commonly used doses of CAB-resistant patients are poorly understood. Design and methods: A multicenter retrospective study was designed to collect a large series of resistant prolactinoma patients, defined by uncontrolled hyperprolactinemia on CAB ≥2.0 mg weekly. Results: Ninety-two patients (50 F, 42 M) were analyzed. At diagnosis, most had macroprolactinomas (82.6%); males were significantly older than females (P=0.0003) and presented with a more aggressive disease. A genetic basis was identified in 12 patients. Thirty-six patients (39.1%) received only medical therapy, most underwent surgery (60.9%, including multiple interventions in 10.9%), and 14.1% received postoperative radiotherapy. Eight patients developed late CAB resistance (8.7%). The median maximal weekly dose of CAB (CAB max/w) was 3.5 mg (2.0–10.5). Despite a higher CAB max/w in patients treated with multimodal therapy (P=0.003 vs exclusive pharmacological treatment), a debulking effect of surgery was shown in 14 patients, with a higher rate of PRL control (P=0.006) and a significant reduction in CAB max/w (P=0.001) postoperatively. At last follow-up (median 88 months), PRL normalization and tumor disappearance were achieved in 28 and 19.9% of the patients respectively, with no significant sex-related difference observed in CAB max/w or disease control. Mortality was 4.8%, with four patients developing aggressive tumors (4.3%) and three a pituitary carcinoma (3.3%). Conclusion: CAB-resistant prolactinomas remain a serious concern. Surgical debulking, newer therapeutic strategies, and early diagnosis of genetic forms could help to improve their outcome.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1530/eje-12-0236

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 209

Metadata

Authors
Vroonen, L., Jaffrain-Rea, M.-L., Petrossians, P., Tamagno, G., Chanson, P., Vilar, L., Borson-Chazot, F., Naves, L. A., Brue, T., Gatta, B., Delemer, B., Ciccarelli, E., Beck-Peccoz, P., Caron, P., Daly, A. F., & Beckers, A.
Venue
European Journal of Endocrinology
Published
2012-11
Volume
167
Issue
5
Pages
651-662
ISSN
  • 0804-4643 (ISSN-L)
  • 1479-683X
OpenAlex
W2123338693
Cited by
209
References
2
FWCI
8.74
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. https://app.cochat.ai/papers/10.1530/eje-12-0236
The paper
Vroonen, L., Jaffrain-Rea, M.-L., Petrossians, P., Tamagno, G., Chanson, P., Vilar, L., Borson-Chazot, F., Naves, L. A., Brue, T., Gatta, B., Delemer, B., Ciccarelli, E., Beck-Peccoz, P., Caron, P., Daly, A. F., & Beckers, A. (2012). Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. European Journal of Endocrinology. https://doi.org/10.1530/eje-12-0236

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.